Cucurbita moschata Duchesne (Cucurbitaceae) is a plant food highly appreciated for the content of nutrients and bioactive compounds, including polyphenols and carotenoids, which contribute to its antioxidant and antimicrobial capacities. The purpose of this study was to identify phenolic acids and flavonoids of Cucurbita moschata Duchesne using high-performance liquid chromatography–diode array detection–electrospray ionization tandem mass spectrometry (HPLC–DAD–ESI-MS) at different ripening stages (young, mature, ripened) and determine its antioxidant and antimicrobial activities. According to the results, phenolic acids and flavonoids were dependent on the maturity stage. The mature fruits contain the highest total phenolic and flavonoids contents (97.4 mg GAE. 100 g⁻¹ and 28.6 mg QE. 100 g⁻¹).A total of 33 compounds were identified. Syringic acid was the most abundant compound (37%), followed by cinnamic acid (12%) and protocatechuic acid (11%). Polyphenol extract of the mature fruits showed the highest antioxidant activity when measured by DPPH (0.065 μmol TE/g) and ABTS (0.074 μmol TE/g) assays. In the antimicrobial assay, the second stage of ripening had the highest antibacterial activity. Staphylococcus aureus was the most sensitive strain with an inhibition zone of 12 mm and a MIC of 0.75 mg L⁻¹. The lowest inhibition zone was obtained with Salmonella typhimurium (5 mm), and the MIC value was 10 mg L⁻¹.

Chronic bacterial prostatitis (CBP) is caused by bacterial infection, commonly treated with fluoroquinolones. Due to rising antibiotic resistance, alternative therapies such as phytotherapy are being explored. Lycopene, a potential antioxidant with anti-inflammatory properties, is a candidate for such therapy. This study aims to evaluate lycopene’s therapeutic effects alone or with cephalexin against chronic prostate infections induced by Staphylococcus aureus using the Wistar rat model. The CBP model was established by introducing S. aureus through the urethra into the prostatic duct in 25 rats, confirming infection via uriculture and spermoculture analysis. Infected rats (n = 21) were grouped randomly: G1 (control), G2 (lycopene), G3 (cephalexin), and G4 (lycopene/cephalexin), in addition to negative control (G5) with healthy rats. Treatments were administered intragastrically, two times per day for 2 weeks: lycopene (10 mg/kg), cephalexin (2.5 mg/kg), or both. Biological samples (blood, urine, and prostate specimens) were collected for microbiological and histological analysis. The results showed a significant reduction in bacterial counts in urine and prostate (p < 0.01), especially in the group treated with both lycopene and cephalexin. This group also exhibited notable anti-inflammatory effects compared to single-treatment and control groups. In conclusion, lycopene combined with cephalexin demonstrated a beneficial synergistic effect, indicating its potential as an effective treatment for CBP caused by S. aureus.